Literature DB >> 33879786

Epigenomic landscape of human colorectal cancer unveils an aberrant core of pan-cancer enhancers orchestrated by YAP/TAZ.

Giulia Della Chiara1,2,3,4, Federica Gervasoni1,2,3,4, Michaela Fakiola1,2, Chiara Godano2,3,5, Claudia D'Oria1,2,3,4, Luca Azzolin6, Raoul Jean Pierre Bonnal1,2, Giulia Moreni2,7, Lorenzo Drufuca1,2, Grazisa Rossetti1,2, Valeria Ranzani2, Ramona Bason1,2,4, Marco De Simone2,8, Francesco Panariello4,9, Ivan Ferrari4, Tanya Fabbris2, Francesca Zanconato6, Mattia Forcato10, Oriana Romano10, Jimmy Caroli10, Paola Gruarin2, Maria Lucia Sarnicola2, Michelangelo Cordenonsi6, Alberto Bardelli11,12, Nicola Zucchini13, Andrea Pisani Ceretti14, Nicolò Maria Mariani14, Andrea Cassingena15, Andrea Sartore-Bianchi15,16, Giuseppe Testa3,16,17, Luca Gianotti18, Enrico Opocher14,19, Federica Pisati20, Claudio Tripodo21,22, Giuseppe Macino23, Salvatore Siena15,16, Silvio Bicciato10, Stefano Piccolo24,25, Massimiliano Pagani26,27,28,29.   

Abstract

Cancer is characterized by pervasive epigenetic alterations with enhancer dysfunction orchestrating the aberrant cancer transcriptional programs and transcriptional dependencies. Here, we epigenetically characterize human colorectal cancer (CRC) using de novo chromatin state discovery on a library of different patient-derived organoids. By exploring this resource, we unveil a tumor-specific deregulated enhancerome that is cancer cell-intrinsic and independent of interpatient heterogeneity. We show that the transcriptional coactivators YAP/TAZ act as key regulators of the conserved CRC gained enhancers. The same YAP/TAZ-bound enhancers display active chromatin profiles across diverse human tumors, highlighting a pan-cancer epigenetic rewiring which at single-cell level distinguishes malignant from normal cell populations. YAP/TAZ inhibition in established tumor organoids causes extensive cell death unveiling their essential role in tumor maintenance. This work indicates a common layer of YAP/TAZ-fueled enhancer reprogramming that is key for the cancer cell state and can be exploited for the development of improved therapeutic avenues.

Entities:  

Year:  2021        PMID: 33879786     DOI: 10.1038/s41467-021-22544-y

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


  63 in total

Review 1.  Transcriptional Addiction in Cancer.

Authors:  James E Bradner; Denes Hnisz; Richard A Young
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

2.  Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.

Authors:  Jae-Seok Roe; Chang-Il Hwang; Tim D D Somerville; Joseph P Milazzo; Eun Jung Lee; Brandon Da Silva; Laura Maiorino; Hervé Tiriac; C Megan Young; Koji Miyabayashi; Dea Filippini; Brianna Creighton; Richard A Burkhart; Jonathan M Buscaglia; Edward J Kim; Jean L Grem; Audrey J Lazenby; James A Grunkemeyer; Michael A Hollingsworth; Paul M Grandgenett; Mikala Egeblad; Youngkyu Park; David A Tuveson; Christopher R Vakoc
Journal:  Cell       Date:  2017-07-27       Impact factor: 41.582

3.  [Work-hour structure for pharmacists' aides].

Authors:  B Frank
Journal:  Pharmazie       Date:  1972-10       Impact factor: 1.267

4.  Biosynthesis of prostaglandins E2 and F2-alpha from tritium-labelled arachidonic acid by rat stomach homogenates.

Authors:  C Pace-Asciak; L S Wolfe
Journal:  Biochim Biophys Acta       Date:  1970-12-15

Review 5.  Cancer genetics and epigenetics: two sides of the same coin?

Authors:  Jueng Soo You; Peter A Jones
Journal:  Cancer Cell       Date:  2012-07-10       Impact factor: 31.743

6.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

7.  Enhancer alterations in cancer: a source for a cell identity crisis.

Authors:  Ken J Kron; Swneke D Bailey; Mathieu Lupien
Journal:  Genome Med       Date:  2014-09-23       Impact factor: 11.117

8.  Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.

Authors:  Guoqiang Yi; Albertus T J Wierenga; Francesca Petraglia; Pankaj Narang; Eva M Janssen-Megens; Amit Mandoli; Angelika Merkel; Kim Berentsen; Bowon Kim; Filomena Matarese; Abhishek A Singh; Ehsan Habibi; Koen H M Prange; André B Mulder; Joop H Jansen; Laura Clarke; Simon Heath; Bert A van der Reijden; Paul Flicek; Marie-Laure Yaspo; Ivo Gut; Christoph Bock; Jan Jacob Schuringa; Lucia Altucci; Edo Vellenga; Hendrik G Stunnenberg; Joost H A Martens
Journal:  Cell Rep       Date:  2019-01-22       Impact factor: 9.423

9.  Systematic pan-cancer analysis of tumour purity.

Authors:  Dvir Aran; Marina Sirota; Atul J Butte
Journal:  Nat Commun       Date:  2015-12-04       Impact factor: 14.919

10.  Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.

Authors:  Francesca Zanconato; Giusy Battilana; Mattia Forcato; Letizia Filippi; Luca Azzolin; Andrea Manfrin; Erika Quaranta; Daniele Di Biagio; Gianluca Sigismondo; Vincenza Guzzardo; Pascale Lejeune; Bernard Haendler; Jeroen Krijgsveld; Matteo Fassan; Silvio Bicciato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Nat Med       Date:  2018-09-17       Impact factor: 53.440

View more
  5 in total

1.  Dynamic Chromatin States Coupling with Key Transcription Factors in Colitis-Associated Colorectal Cancer.

Authors:  Lin Chen; Zhihui Luo; Chen Zhao; Qinglan Li; Yingjie Geng; Yong Xiao; Ming-Kai Chen; Lianyun Li; Zhen-Xia Chen; Min Wu
Journal:  Adv Sci (Weinh)       Date:  2022-06-16       Impact factor: 17.521

Review 2.  Transcriptional Regulation of the Hippo Pathway: Current Understanding and Insights from Single-Cell Technologies.

Authors:  Sayantanee Paul; Shiqi Xie; Xiaosai Yao; Anwesha Dey
Journal:  Cells       Date:  2022-07-17       Impact factor: 7.666

3.  Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.

Authors:  Ariane Hallermayr; Tobias Wohlfrom; Verena Steinke-Lange; Anna Benet-Pagès; Florentine Scharf; Ellen Heitzer; Ulrich Mansmann; Christopher Haberl; Maike de Wit; Holger Vogelsang; Markus Rentsch; Elke Holinski-Feder; Julia M A Pickl
Journal:  J Hematol Oncol       Date:  2022-09-02       Impact factor: 23.168

4.  A local tumor microenvironment acquired super-enhancer induces an oncogenic driver in colorectal carcinoma.

Authors:  Jia Xu; Tiphaine C Martin; Royce W Zhou; Alexis L Zachem; John He; Sait Ozturk; Deniz Demircioglu; Ankita Bansal; Andrew P Trotta; Bruno Giotti; Berkley Gryder; Yao Shen; Xuewei Wu; Saul Carcamo; Kaitlyn Bosch; Benjamin Hopkins; Alexander Tsankov; Randolph Steinhagen; Drew R Jones; John Asara; Jerry E Chipuk; Rachel Brody; Steven Itzkowitz; Iok In Christine Chio; Dan Hasson; Emily Bernstein; Ramon E Parsons
Journal:  Nat Commun       Date:  2022-10-17       Impact factor: 17.694

Review 5.  The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.

Authors:  Richard Cunningham; Carsten Gram Hansen
Journal:  Clin Sci (Lond)       Date:  2022-02-11       Impact factor: 6.124

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.